News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEvents
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Anne H. Gross, PhD, RN, NEA-BC, FAAN

Advertisement

Articles by Anne H. Gross, PhD, RN, NEA-BC, FAAN

Oncology Nursing Practice in 2020: The Challenges and Opportunities of the COVID-19 Pandemic

ByAnne H. Gross, PhD, RN, NEA-BC, FAAN
December 11th 2020

Early on, oncology nurses knew that cancer wasn’t going to stop for COVID-19, and so neither could they.

Advertisement

Latest Updated Articles

  • Oncology Nursing Practice in 2020: The Challenges and Opportunities of the COVID-19 Pandemic
    Oncology Nursing Practice in 2020: The Challenges and Opportunities of the COVID-19 Pandemic

    Published: December 11th 2020 | Updated:



Advertisement
Advertisement

Trending on Oncology Nursing News

1

Sub-Q Mosunetuzumab Wins FDA Approval in R/R Follicular Lymphoma

2

Opinion: CAR T-Cell Therapy Shows Promise in Gastric and GEJ Cancers

3

Real, Placebo Acupuncture Improve Cognitive Outcomes in Breast Cancer Survivors

4

1L Giredestrant Yields Improved IDFS vs ET in ER+/HER2– Breast Cancer

5

Maintenance Tucatinib/HP Improves PFS Post 2-Year Mark in HER2+ mBC

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us